Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Lipid Disorder
Interventions: moderate- or high-intensity statin/ rosuvastatin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, Erlotinib, Prednisone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more

Conditions: Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm, Nerve Sheath Neoplasm, Pituitary Gland Adenoma, Schwannoma
Interventions: Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Aging
Interventions: NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 40 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: DAC-HYP; Biological
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure
Interventions: LMI 1195-101; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Hartford, Connecticut • New Haven, Connecticut

Conditions: COPD, Smoking
Interventions: Cohort I, Cohort II; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
Interventions: None-Observation Only; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 997 participants
Timeline: 2003 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Shigellosis
Interventions: Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Anemia, Aplastic
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 15 Years to 90 Years
Enrollment: 2,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Volunteers
Interventions: Hyperpolarized [13C] Pyruvate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more

Conditions: Rheumatoid Arthritis, Healthy Controls
Interventions: Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment; Other
Lead sponsor: Duke University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, ECC5004; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Malignant Glioma
Interventions: Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: ProAgio Dose Levels (DL) 1,2,3,4, Gemcitabine, nab paclitaxel; Drug
Lead sponsor: ProDa BioTech, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COVID-19, Coronavirus Infection, Coronavirus, SARS-CoV-2
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,316 participants
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Thyroglossal Duct Cysts
Interventions: Post-surgical drain, No post-surgical drain; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 17 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 37
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Celiac Disease
Interventions: Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C; Drug · Other
Lead sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more

Search by objective public record fields.

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

IV Administration of ChromaDex's Niagen® as Compared to NAD+

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function

Cognitive Impairement In Frontotemporal Dementia

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

Lead-212 PSV359 Therapy for Patients With Solid Tumors

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

FTIH of ECC5004 in Healthy and Diabetic Participants

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

St. Jude Tracking of Viral and Host Factors Associated With COVID-19

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)